Cell encapsulation as a potential nondietary therapy for maternal phenylketonuria

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 3, 2009, Pages 289.e1-289.e6

  Santillan, Donna A ^a   Santillan, Mark K ^a   Hunter, Stephen K ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

alginate microspheres; cell encapsulation; immunoisolation; phenylalanine hydroxylase; phenylketonuria

Indexed keywords

ALGINIC ACID; MICROSPHERE; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PLASMID DNA;

ARTICLE; CELL CULTURE; CELL ENCAPSULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; TANDEM MASS SPECTROMETRY; TERATOGENICITY; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

EID: 69349089916     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.05.035     Document Type: Article

References (43)

1. Scriver C.R., and Kaufmann S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease (2001), McGraw-Hill, New York
2. Scriver C.R., and Clow C.L. Phenylketonuria and other phenylalanine hydroxylation mutants in man. Annu Rev Genet 14 (1980) 179-202
3. Udenfriend S., and Cooper J.R. The enzymatic conversion of phenylalanine to tyrosine. J Biol Chem 194 (1952) 503-511
4. National Institutes of Health. Phenylketonuria: screening and management consensus development conference statement. NIH 17 (2000) 1-27 October 16-18
5. Wappner R., Cho S., Kronmal R.A., Schuett V., and Seashore M.R. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. Pediatrics 104 (1999) e68
6. Sullivan J.E., and Chang P. Review: emotional and behavioral functioning in phenylketonuria. J Pediatr Psychol 24 (1999) 281-299
7. MacDonald A. Diet and compliance in phenylketonuria. Eur J Pediatr 159 suppl 2 (2000) S136-S141
8. Walter J.H., White F.J., Hall S.K., et al. How practical are recommendations for dietary control in phenylketonuria?. Lancet 360 (2002) 55-57
9. Koch R., Friedman E., Azen C., et al. The international collaborative study of maternal phenylketonuria: status report 1998. Eur J Pediatr 159 suppl 2 (2000) S156-S160
10. Koch R., Hanley W., Levy H., et al. The maternal phenylketonuria international study: 1984-2002. Pediatrics 112 (2003) 1523-1529
11. Levy H.L., and Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 53 (1996) 176-184
12. Fisch R.O., Walker W.A., and Anderson J.A. Prenatal and postnatal developmental consequences of maternal phenylketonuria. Pediatrics 37 (1966) 979-986
13. Lenke R.R., and Levy H.L. Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of untreated and treated pregnancies. N Engl J Med 303 (1980) 1202-1208
14. Rouse B., Lockhart L., Matalon R., et al. Maternal phenylketonuria pregnancy outcome: a preliminary report of facial dysmorphology and major malformations. J Inherit Metab Dis 13 (1990) 289-291
15. Koch R., Azen C., Friedman E., et al. Research design, organization, and sample characteristics of the maternal PKU collaborative study. Pediatrics 112 (2003) 1519-1522
16. Koch R., Hanley W., Levy H., et al. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. J Inherit Metab Dis 13 (1990) 641-650
17. Ng T.W., Rae A., Wright H., Gurry D., and Wray J. Maternal phenylketonuria in Western Australia: pregnancy outcomes and developmental outcomes in offspring. J Paediatr Child Health 39 (2003) 358-363
18. Coromili V., and Chang T.M. Polydisperse dextran as a diffusing test solute to study the membrane permeability of alginate polylysine microcapsules. Biomater Artif Cells Immobilization Biotechnol 21 (1993) 427-444
19. Vajro P., Strisciuglio P., Houssin D., et al. Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med 329 (1993) 363
20. Fiege B., and Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr 150 (2007) 627-630
21. Koch R., Moseley K.D., Yano S., Nelson Jr. M., and Moats R.A. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab 79 (2003) 110-113
22. Matalon R., Michals-Matalon K., Bhatia G., et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis 30 (2007) 153-158
23. Schindeler S., Ghosh-Jerath S., Thompson S., et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab 91 (2007) 48-54
24. Liu T.J., Kay M.A., Darlington G.J., and Woo S.L. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. Somat Cell Mol Genet 18 (1992) 89-96
25. Eisensmith R.C., and Woo S.L. Gene therapy for phenylketonuria. Eur J Pediatr 155 suppl 1 (1996) S16-S19
26. Nagasaki Y., Matsubara Y., Takano H., et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr Res 45 (1999) 465-473
27. Fang B., Eisensmith R.C., Li X.H., et al. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1 (1994) 247-254
28. Oh H.J., Park E.S., Kang S., Jo I., and Jung S.C. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Pediatr Res 56 (2004) 278-284
29. Mochizuki S., Mizukami H., Ogura T., et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 11 (2004) 1081-1086
30. Ding Z., Georgiev P., and Thony B. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther 13 (2006) 587-593
31. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99 (2002) 11854-11859
32. Sarkissian C.N., and Gamez A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?. Mol Genet Metab 86 suppl 1 (2005) S22-S26
33. Hoskins J.A., Jack G., Wade H.E., et al. Enzymatic control of phenylalanine intake in phenylketonuria. Lancet 1 (1980) 392-394
34. Inoue S., Matsunaga Y., Iwane H., Sotomura M., and Nose T. Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack. Biochem Biophys Res Commun 141 (1986) 165-170
35. Bourget L., and Chang T.M. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. FEBS Lett 180 (1985) 5-8
36. Gamez A., Sarkissian C.N., Wang L., et al. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. Mol Ther 11 (2005) 986-989
37. Wang L., Gamez A., Sarkissian C.N., et al. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria. Mol Genet Metab 86 (2005) 134-140
38. O'Shea G.M., Goosen M.F., and Sun A.M. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim Biophys Acta 804 (1984) 133-136
39. Cochrum K., Jemtrud S., and Dorian R. Successful xenografts in mice with microencapsulated rat and dog islets. Transplant Proc 27 (1995) 3297-3301
40. Gianello P., and Dufrane D. Correction of a diabetes mellitus type 1 on primate with encapsulated islet of pig pancreatic transplant. [French]. Bull Mem Acad R Med Belg 162 (2007) 439-450
41. Hunter S.K., Wang Y., Weiner C.P., and Niebyl J. Encapsulated beta-islet cells as a bioartificial pancreas to treat insulin-dependent diabetes during pregnancy. Am J Obstet Gynecol 177 (1997) 746-752
42. Hunter S.K., Kao J.M., Wang Y., Benda J.A., and Rodgers V.G. Promotion of neovascularization around hollow fiber bioartificial organs using biologically active substances. ASAIO J 45 (1999) 37-40
43. Levy H.L., Waisbren S.E., Guttler F., et al. Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics 112 (2003) 1548-1552